Collaborations & Alliances

Shionogi & Co., Hsiri Therapeutics Expand Infectious Diseases Alliance

Shionogi will have exclusive worldwide rights to develop, manufacture, and commercialize the compounds generated from the collaboration

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Shionogi & Co., Ltd. has entered into a new license agreement with Hsiri Therapeutics, Inc. for a collaborative research and development program to discover and develop additional novel therapeutics for non-tuberculous mycobacterial (NTM) diseases and tuberculosis (TB). This new collaboration will include technology that complements Shionogi’s earlier collaboration arrangement with Hsiri.  The new technology licensed from Hsiri has a novel mechanism of action that will be complement...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters